[20-Mar-2023 Addendum: the links below to the WHO website no longer work. Our application can now be downloaded here. The summary of the WHO Secretariat’s decision to include co-packaged ORS and zinc is available here.] Our application to get co-packaged ORS and zinc on the WHO Model Essential Medicines List for Children (EMLc) is now […]
Search Results for: WHO EML
Update 2: Co-packaged ORS/Zinc on the WHO Essential Medicines List for Children (EMLc)
27 July 2018 by
We met with WHO representatives on 25-Jun-18 in Geneva to discuss our application It’s a year since I last updated you on our progress towards getting co-packaged ORS and zinc on WHO’s Essential Medicines List for Children (EML). You can read the last update here. In summary, a lot of progress has been made and […]
Evidence gathering for our application to get co-packaged ORS and Zinc on the WHO Essential Medicines List (EML)
1 December 2017 by
This photo came through yesterday (30-Nov-17) on our project WhatsApp Group. It features Akufuna and Lois, the two Keepers Zambia Foundation staff in Western Province. They are at a health centre and Akufuna is collecting the stock level information for ORS and Zinc since Jan-15. We expect that this survey will provide part of the […]
Update: Co-packaged ORS/Zinc on the WHO Essential Medicines List for Children (EMLc)
7 June 2017 by
As reported earlier, we are working to get co-packaged ORS and Zinc on WHO’s Essential Medicines List for Children (EMLc). We are doing this because the circumstantial evidence suggests that while ORS and Zinc are listed separately on the EMLc they will be procured and supplied separately and rarely dispensed together. The combined use of […]
Making the Case for Inclusion of Co-packaged ORS/Zinc on the WHO Model List of Essential Medicines for Children (EMLc)
27 March 2017 by
The WHO Model List of Essential Medicines For four decades, the World Health Organisation (WHO) has devoted substantial effort to an essential medicines programme that seeks to improve access to the most needed drugs and devices. The meeting of the 21st WHO Expert Committee on the Selection and Use of Essential Medicines will be held […]
So how was the Kit Yamoyo Legacy achieved?
5 July 2023 by
In a recent post I tried to quantify the Kit Yamoyo Legacy and indicated that I’d follow-up with a post on how we think this legacy was achieved. We think it boils down to eight principles and furthermore we think that if ‘foreign bodies’ (international NGOs and aid agencies) followed these principles, we would see […]
Old status
Last updated: 20-Feb-22 To keep up to date with the latest news please subscribe to our blog. ColaLife team deployment Simon Berry – part-time – UK-based – building on the WHO Essential Medicines List success through the ORS/Zinc Co-pack Alliance (ORSZCA) which was launched on 19-Jan-22. Jane Berry – part-time – UK-based – working on […]
Top 5 Achievements for 2019
30 December 2019 by
2009’s top 10 | 2010’s top 10 | 2011’s top 10 | 2012’s top 10 | 2013’s top 10 2014’s top 10 | 2015’s top 10 | 2016’s top 10 | 2017’s top 10 | 2018’s top 10 We’ve had 10 years of Top Tens: an exciting decade when ColaLife achieved much more than we ever expected. 2019 […]
Success: WHO adds co-packaged ORS and Zinc to its Essential Medicines List
9 July 2019 by
Our application* to get co-packaged ORS and zinc on the WHO Essential Medicines List has been successful. This is game-changer. It moves ColaLife’s work out of the ‘innovation box’ into the mainstream of global children’s public health – with better designed, easier-to-dispense diarrhoea treatment available for sick children – potentially everywhere. A summary of the […]
Application submitted to WHO to add co-packaged ORS and zinc to the WHO Essential Medicines List
12 November 2018 by
Today (12-Nov-18) was a very big day for ColaLife. It was on 28-Jan-17, when the penny dropped for me. Why isn’t co-packaged ORS and Zinc on WHO’s Essential Medicines List for Children (EMLc)? ORS is listed and zinc is listed and this has been the case for nearly 15 years but still only about 7% of […]
